Previous studies have shown that IL‐33 signalling via ST2L exhibits cardioprotective effects against various cardiovascular diseases (e.g. myocardial infarction, atherosclerosis, pulmonary arterial hypertension, cardiac hypertrophy and fibrosis) by modulating immune and inflammatory responses 6, 11, 34. This evidence concerns the gene IL33 and cardiac hypertrophy.